查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1524240

PARP 抑制剂生物标记市场、副产品（试剂盒、检测）、服务（BRCA 1 和2 测试、HRD 测试、HRR 测试）、应用（乳腺癌、卵巢癌）、最终用途（医院和诊所、诊断实验室）- 全球预测（2024 - 2032）

PARP Inhibitor Biomarkers Market, By Product (Kits, Assays), Service (BRCA 1 & 2 Testing, HRD Testing, HRR Testing), Application (Breast Cancer, Ovarian Cancer), End-use (Hospitals & Clinics, Diagnostic Laboratories) - Global Forecast (2024 - 2032)
出版日期: | 出版商: Global Market Insights Inc. | 英文 165 Pages | 商品交期: 2-3个工作天内

价格
简介目录

在专注于扩大 PARP 抑制剂应用的持续研发工作的推动下，全球 PARP 抑制剂生物标记市场从 2024 年到 2032 年的复合年增长率将超过 8.3%。这种持续探索的目的是发现现有用途之外的新治疗途径，为不同的患者群体提供更多的治疗选择。这些药物开发措施对于推进精准医学和根据特定基因谱和生物标记定制治疗至关重要。这些努力带来了创新，有助于扩大 PARP 抑制剂的临床应用，增强其在肿瘤学和未来其他潜在治疗领域的作用。

PARP 抑制剂生物标记领域的竞争中心在于识别和验证癌症治疗中标靶治疗的预测生物标记。辉瑞、阿斯特捷利康和默克等主要 PARP 抑制剂生物标记供应商正在不断升级研究，并专注于功效和抗药性机制。新兴生物技术公司透过创新的生物标记发现平台做出贡献，增强了市场活力。

整个 PARP 抑制剂生物标记行业根据产品、服务、应用、最终用途和地区进行分类。

在 PARP 抑制剂生物标记市场中，预计 2024 年至 2032 年期间检测领域将出现强劲的复合年增长率。这些技术能够更精确地识别和表征与 PARP 抑制剂反应相关的生物标记物，从而增强患者分层和治疗效果。随着检测变得更加复杂和方便，医疗保健提供者可以根据个别生物标记概况更好地客製化治疗方法，从而优化患者的治疗结果。这一趋势凸显了生物标记驱动的方法在肿瘤学和其他治疗领域中日益重要，促使 PARP 抑制剂生物标记成为临床实践和药物开发的重要工具。

到 2032 年，HRD 检测领域将在 PARP 抑制剂生物标记市场中占据重要份额，因为它们在识别从 PARP 抑制剂治疗中受益的患者方面发挥着重要作用。 HRD 测试评估影响 DNA 修復机制的遗传异常，例如 BRCA 突变，可以预测对 PARP 抑制剂的反应。随着这些生物标记在治疗选择中的预测价值得到认可，医疗保健提供者正在将 HRD 测试纳入常规肿瘤学实践中。这一趋势反映了向个人化医疗的更广泛转变，其中生物标记驱动的方法提高了癌症护理中的治疗精度和患者结果。

欧洲 PARP 抑制剂生物标记市场从 2024 年到 2032 年将呈现强劲的复合年增长率。欧洲医疗保健系统越来越多地采用生物标记驱动的癌症治疗方法，提高患者的治疗效果和成本效益。根据欧洲癌症资讯系统 ECIS 的数据，截至 2022 年 4 月，欧洲 21% 的乳癌病例发生在 50 岁以下的女性，这是发病高峰年龄层。另外 35% 的患者年龄在 50-64 岁之间，其余患者年龄在 65 岁及以上。

欧洲监管机构一直支持创新疗法和基于生物标记的诊断，促进更快地采用和融入临床实践。随着人们对 PARP 抑制剂在治疗具有特定生物标记的癌症方面的功效的认识不断增强，它们在欧洲肿瘤中心的使用也不断增加，突显了它们在现代癌症治疗策略中的关键作用。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

  • 产业生态系统分析
  • 产业影响力
    • 成长动力
      • 乳癌盛行率增加
      • 基因组技术的进步
      • 癌症治疗支出增加
      • 越来越多地采用个人化医疗和精准治疗
    • 产业陷阱与挑战
      • PARP 抑制剂生物标记检测试剂盒和检测方法成本高昂
      • 对 PARP 抑制剂生物标记的认识和理解有限
  • 成长潜力分析
  • 技术景观
  • 监管环境
  • 波特的分析
  • PESTEL分析

第 4 章：竞争格局

  • 介绍
  • 公司市占率分析
  • 竞争定位矩阵
  • 战略展望矩阵

第 5 章：市场估计与预测：按产品分类，2021 - 2032 年

  • 主要趋势
  • 套件
  • 化验

第 6 章：市场估计与预测：按服务分类，2021 - 2032 年

  • 主要趋势
  • BRCA（乳癌基因）1 和 2 测试
  • HRD（同源重组缺陷）测试
  • HRR（同源重组修復）测试
  • 其他服务

第 7 章：市场估计与预测：按应用分类，2021 - 2032

  • 主要趋势
  • 乳癌
  • 卵巢癌
  • 其他应用

第 8 章：市场估计与预测：按最终用途，2021 - 2032 年

  • 主要趋势
  • 医院和诊所
  • 诊断实验室
  • 学术及研究机构
  • 其他最终用户

第 9 章：市场估计与预测：按地区，2021 - 2032

  • 主要趋势
  • 北美洲
    • 我们
    • 加拿大
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 义大利
    • 荷兰
    • 欧洲其他地区
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 亚太地区其他地区
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
    • 拉丁美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 南非
    • 阿联酋
    • 中东和非洲其他地区

第 10 章：公司简介

  • Agilent Technologies, Inc.
  • Ambry Genetics
  • Amoy Diagnostics Co., Ltd.
  • Centogene N.V
  • Illumina, Inc.
  • Invitae Corporation
  • Myriad Genetics, Inc.
  • Neogenomics, Inc.
  • QIAGEN N.V.
  • Thermo Fisher Scientific Inc.
简介目录
Product Code: 9191

Global PARP Inhibitor Biomarkers Market will record over 8.3% CAGR from 2024 to 2032, ushered by ongoing research and development efforts focused on broadening the application of PARP inhibitors. This continuous exploration aims to uncover new therapeutic avenues beyond existing uses, enhancing treatment options for diverse patient populations. These drug development initiatives are pivotal in advancing precision medicine and tailoring treatments based on specific genetic profiles and biomarkers. Such endeavors usher innovation and contribute to expanding the clinical utility of PARP inhibitors, reinforcing their role in oncology and potentially other therapeutic areas in the future.

Competition centers in the PARP inhibitor biomarkers sector on identifying and validating predictive biomarkers for targeted therapies in cancer treatment. Key PARP inhibitor biomarkers vendors such as Pfizer, AstraZeneca, and Merck are escalating research, focusing on efficacy and resistance mechanisms. Emerging biotech firms contribute with innovative biomarker discovery platforms, strengthening market dynamics.

The overall PARP inhibitor biomarkers industry is sorted based on product, service, application, end-use, and region.

In the PARP inhibitor biomarkers market, a strong CAGR is predicted for the assay segment over the 2024 to 2032 timeline. These technologies enable more precise identification and characterization of biomarkers associated with PARP inhibitor response, enhancing patient stratification and treatment efficacy. As assays become more sophisticated and accessible, healthcare providers can better tailor therapies based on individual biomarker profiles, optimizing patient outcomes. This trend highlights the growing importance of biomarker-driven approaches in oncology and other therapeutic areas, catapulting the adoption of PARP inhibitor biomarkers as essential tools in clinical practice and drug development.

The HRD testing segment will attain a significant PARP inhibitor biomarkers market share by 2032 because of their role in identifying patients who benefit from PARP inhibitor therapies. HRD testing evaluates genetic abnormalities that affect DNA repair mechanisms, such as BRCA mutations, which can predict response to PARP inhibitors. As these biomarkers gain recognition for their predictive value in treatment selection, healthcare providers are integrating HRD testing into routine oncology practices. This trend reflects a broader shift towards personalized medicine, where biomarker-driven approaches improve treatment precision and patient outcomes in cancer care.

Europe PARP inhibitor biomarkers market will exhibit a robust CAGR from 2024 to 2032. One significant catalyst is the robust healthcare infrastructure and emphasis on advancing precision medicine. European healthcare systems are increasingly adopting biomarker-driven approaches to cancer treatment, enhancing patient outcomes and cost-effectiveness. According to the European Cancer Information System ECIS, as of April 2022, 21% of breast cancer cases in Europe occur in women under 50, the peak incidence age group. Another 35% are diagnosed in women aged 50-64, with the rest in those aged 65 and older.

Regulatory bodies in Europe have been supportive of innovative therapies and biomarker-based diagnostics, facilitating faster adoption and integration into clinical practice. As awareness of PARP inhibitors efficacy in treating cancers with specific biomarkers grows, so does their utilization in European oncology centers, underscoring their pivotal role in modern cancer care strategies.

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Market scope & definitions
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates & calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Increasing prevalence of breast cancer
      • 3.2.1.2 Advancements in genomic technologies
      • 3.2.1.3 Rising expenditure for cancer treatment
      • 3.2.1.4 Growing adoption of personalized medicine and precision therapy
    • 3.2.2 Industry pitfalls & challenges
      • 3.2.2.1 High cost of PARP inhibitor biomarker test kits and assays
      • 3.2.2.2 Limited awareness and understanding of PARP inhibitors biomarkers
  • 3.3 Growth potential analysis
  • 3.4 Technological landscape
  • 3.5 Regulatory landscape
  • 3.6 Porter's analysis
  • 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company market share analysis
  • 4.3 Competitive positioning matrix
  • 4.4 Strategy outlook matrix

Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2032 ($ Mn)

  • 5.1 Key trends
  • 5.2 Kits
  • 5.3 Assays

Chapter 6 Market Estimates and Forecast, By Service, 2021 - 2032 ($ Mn)

  • 6.1 Key trends
  • 6.2 BRCA (Breast cancer gene) 1 & 2 testing
  • 6.3 HRD (Homologous recombination deficiency) testing
  • 6.4 HRR (Homologous recombination repair) testing
  • 6.5 Other services

Chapter 7 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

  • 7.1 Key trends
  • 7.2 Breast cancer
  • 7.3 Ovarian cancer
  • 7.4 Other applications

Chapter 8 Market Estimates and Forecast, By End-Use, 2021 - 2032 ($ Mn)

  • 8.1 Key trends
  • 8.2 Hospitals and clinics
  • 8.3 Diagnostic laboratories
  • 8.4 Academic and research institutes
  • 8.5 Other end-users

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

  • 9.1 Key trends
  • 9.2 North America
    • 9.2.1 U.S.
    • 9.2.2 Canada
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 France
    • 9.3.4 Spain
    • 9.3.5 Italy
    • 9.3.6 Netherlands
    • 9.3.7 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 South Korea
    • 9.4.6 Rest of Asia Pacific
  • 9.5 Latin America
    • 9.5.1 Brazil
    • 9.5.2 Mexico
    • 9.5.3 Argentina
    • 9.5.4 Rest of Latin America
  • 9.6 Middle East and Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 South Africa
    • 9.6.3 UAE
    • 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

  • 10.1 Agilent Technologies, Inc.
  • 10.2 Ambry Genetics
  • 10.3 Amoy Diagnostics Co., Ltd.
  • 10.4 Centogene N.V
  • 10.5 Illumina, Inc.
  • 10.6 Invitae Corporation
  • 10.7 Myriad Genetics, Inc.
  • 10.8 Neogenomics, Inc.
  • 10.9 QIAGEN N.V.
  • 10.10 Thermo Fisher Scientific Inc.